Navigation Links
TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA
Date:11/12/2008

BLUE BELL, Pa., Nov. 13 /PRNewswire/ -- TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology.

Najib Babul, PharmD, Chief Executive Officer of TheraQuest stated, "Sustained release opioids are the standard of care for the management of chronic pain. Unfortunately, it is easy to defeat the sustained release mechanim of such dosage forms, making them subject to drug diversion and drug abuse. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin(R), thereby minimizing abuse by recreational drug users and drug addicts."

About TQ-1015

TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain. It has been developed using TheraQuest's proprietary abuse deterrent extended release drug delivery system (SECUREL(R)). TQ-1015 is significantly more potent than many current oral therapies, including morphine and oxycodone. It shows robust efficacy in various animal models of acute pain, inflammatory pain and neuropathic pain. TQ-1015 will compete in the $8.3 billion U.S. opioid market.

About SECUREL(R)

Recent experience with extended release opioid pain relievers has shown that intentional crushing or extraction of the active ingredient from the dosage form by addicts and recreational drug users can destroy the timed-release mechanism and result in a rapid surge of drug into the bloodstream. Serious side-effects and death have been reported from such misuse.

SECUREL(R) is TheraQuest's proprietary abuse deterrent extended release technology for oral abusable drugs. SECUREL(R) dosage forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It is also exceedingly difficult for I.V. abusers to extract the active drug from the dosage form using common solvents, including alcohol.

About TheraQuest

TheraQuest Biosciences, Inc. (http://www.theraquestinc.com) is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest's strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.

TheraQuest is funded in part by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology Partners of Southeastern Pennsylvania.

SECUREL(R) and OxyContin(R) are registered trademarks of TheraQuest Biosciences, Inc., and Purdue Pharma LP., respectively.


'/>"/>
SOURCE TheraQuest Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Disability payments may spur drug abuse
2. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
3. Inhalant Abuse Prevention Program to Be Launched in Maryland Schools
4. Research examines connection between substance abuse and violence
5. Steroids Are Abused for Skin, Not Just Muscles
6. L.A. Author, TV Personality and Substance Abuse Specialist Discusses Struggle to Break Bad-girl Syndrome Oct. 26-28 in Baltimore
7. Dealing with stress as a treatment for alcohol abuse
8. Culture can Affect Access to Alcohol, Drug Abuse Treatment for Rural Youth
9. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
10. CHPA Commends Senator Biden on Legislation Aimed at Curbing Medicine-Abuse Trend
11. Substance abuse practitioners ask what is recovery?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... call for entries to the 7th Edition of International Social Design Awards. ... Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , February 24, 2017 Following ... Israel , s ... $ 250 M w ound care ... file s BST for inclusion in ... national healthcare reimbursement system   E-QURE Corp. ...
(Date:2/24/2017)... and Markets has announced the addition of the "Hemophilia Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Hemophilia ... market? What are the unit prices and annual treatment ...
(Date:2/24/2017)... HILL, N.C. , Feb. 24, 2017 /PRNewswire/ ... are exploring ways to increase their self-service capabilities ... Health Care Providers (HCPs). New research ... many pharma organizations have developed self-service website portals ... electronically.  This is just one of many findings ...
Breaking Medicine Technology: